Multi-ingredient supplement improved vascular markers within hours and over 6 months
A nutritional supplement designed to target several aging-related pathways was linked to measurable gains in vascular health markers in a 6-month randomized trial. The signals appeared early and then persisted, with improvements in endothelial function seen within 1 hour of the first dose and between-group differences in systolic blood pressure and arterial stiffness emerging over the longer course of treatment.
Those findings matter because vascular dysfunction rarely begins with a heart attack or stroke. It starts earlier, with a vessel wall that loses flexibility, endothelium that no longer responds normally to blood flow, and blood pressure control that gradually becomes less stable. The trial focused on those upstream markers rather than hard cardiovascular outcomes, but the biology points in a clinically familiar direction: healthier endothelial signaling and lower arterial stiffness can reduce cardiac strain if the effect is durable.
The study, published in European Heart Journal Open, tested NOVOS Core, a multi-component supplement containing 12 vitamins, minerals, amino acids, and plant-derived bioactive compounds. Investigators randomized 61 participants, with 33 assigned to the supplement and 28 to placebo, and asked them to take their assigned product once daily for 6 months. The formulation was intended to influence multiple biological processes associated with aging at the same time, rather than leaning on a single compound or pathway.
Endothelial function changed after the first dose
The clearest early signal involved flow-mediated dilation, a standard measure of how well an artery expands when blood flow rises. In practical terms, the test captures endothelial function, which depends heavily on nitric oxide availability and vascular tone. A healthier endothelium responds quickly; a dysfunctional one remains sluggish.
Within 1 hour of the first dose, the supplement group showed an improvement in this measure, while the placebo group remained largely unchanged. The speed of the response suggests an acute vascular effect rather than a structural remodeling process in the artery wall. It also suggests that at least part of the formulation may influence endothelial signaling rapidly, although the study was not built to identify which ingredient drove the change.
Christian Heiss, professor of cardiovascular medicine at the University of Surrey, said the most interesting result was the simultaneous shift across several complementary markers of vascular health. He described the trial as an initial proof of concept for a multi-component approach to vascular aging, while emphasizing that the study was small and relied on biomarkers rather than clinical cardiovascular events.
Blood pressure and arterial stiffness moved in the favorable direction
After 6 months, systolic blood pressure was 6.1 mmHg lower in the supplement group than in the placebo group, based on the adjusted between-group difference. A difference was also seen within an hour of the first dose. In cardiovascular medicine, even modest shifts in systolic pressure can matter when they are sustained, because long-term pressure load drives left ventricular strain, vascular injury, and stroke risk.
The trial also found a 1.18 m/s adjusted difference in pulse wave velocity favoring the supplement group. Pulse wave velocity serves as a marker of arterial stiffness: the faster the pressure wave travels, the stiffer the artery. Stiffer arteries reflect loss of elasticity and are linked to higher cardiovascular risk because they amplify pulsatile load and make blood pressure control more difficult.
The biological logic behind the findings is plausible. Several ingredients in the supplement have been linked individually to endothelial nitric oxide availability, vascular tone, and related pathways. If multiple mechanisms are nudged at once, the end result could be improved vessel responsiveness and less stiff arterial behavior. Still, the trial did not determine which ingredients were active, whether one dominated the effect, or whether the response depended on interactions among compounds.
Why the result should not be read as a disease-prevention claim
The trial measured biomarkers, not clinical events. No one can conclude from these data that the supplement prevents heart attack, stroke, or other cardiovascular complications.
That distinction is critical in a field where surrogate endpoints often improve faster than actual outcomes. A better endothelial test or a lower blood pressure reading can suggest a favorable physiological shift, but it does not prove that patients will live longer or avoid disease if they take the product over time.
The trial also cannot show whether the supplement slows biological aging itself. It examined markers associated with vascular health, not the broader arc of age-related decline. The study period lasted 6 months, so longer-term durability, safety, and real-world effectiveness remain open questions.
Small sample size and industry funding limit the strength of the signal
Only 61 participants were enrolled, which leaves little room to characterize how consistent the response might be across broader populations. Differences in age, baseline cardiovascular risk, diet, medication use, and underlying endothelial status could all influence how much a participant responds to a supplement of this kind. A larger trial would be needed to learn whether the benefit is reproducible and whether some groups respond more strongly than others.
Funding from NOVOS Labs, the manufacturer of the supplement, also deserves attention. Industry support does not invalidate a study, but it does place a premium on independent replication, especially when the intervention combines many active ingredients and the mechanisms remain uncertain. The study’s own limitations make that point plainly: the results are encouraging, but they are not definitive.
One sentence captures the practical takeaway. Biomarkers improved; cardiovascular outcomes were not tested.
Where this leaves cardiovascular prevention
Heiss said the findings should not be interpreted as a replacement for established cardiovascular prevention strategies such as not smoking, physical activity, a healthy diet, maintaining a healthy weight, and appropriate treatment of blood pressure and cholesterol. Those interventions remain the foundation because their benefits are tied to outcomes, not just to surrogate changes in vascular testing.
The study does raise a more interesting question than whether one supplement works in isolation. It asks whether targeting several interacting aging-related pathways at once can produce a measurable physiological effect in the vasculature. That idea is biologically plausible, especially in a system where endothelial signaling, arterial compliance, and blood pressure regulation are tightly linked.
The next step is direct mechanistic testing. Investigators will need to determine whether the pathways the supplement was meant to affect actually changed, whether the vascular gains persist beyond 6 months, and whether any of the observed biomarker shifts translate into fewer cardiovascular events. Until then, the trial sits in an important but narrow space: a small, biomarker-based study showing a signal in vascular health without proving clinical protection.